- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04925232
Transcranial Magnetic Stimulation For Visual Snow Syndrome (TMSVS)
Transcranial Magnetic Stimulation for Visual Snow Syndrome: An Open-Label Feasibility Treatment Trial
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The study will gather information about the treatment of up to 10 people with VS using rTMS. Treated participants will undergo 10 sessions of rTMS administered 5 times a week over 2 weeks. All visits will take place in the University of Colorado School of Medicine NeuroMag/Transcranial Magnetic Stimulation laboratory on University of Colorado Anschutz Medical Campus.
The specific aims for this feasibility study include:
- Determine whether any participant experiences untoward effects of rTMS in the setting of visual snow syndrome and determine the potential drop-out rate of larger study.
Determine the performance of a novel scale (Colorado Visual Snow Scale) and two three psychophysical visual processing tasks
- Determine the standard deviation and test-retest reliability for the novel scale and two visual processing tasks
- Determine whether the visual processing tasks perform similar to performance found by the developer
- Describe changes in outcome measures between pre- and post-treatment with rTMS
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Colorado
-
Aurora, Colorado, United States, 80045
- University of Colorado School of Medicine Anschutz Medical Campus
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- A diagnosis of VS that meets International Headache Society criteria
- Able to provide meaningful informed consent
- Visual snow must be present for more than three months and must be persistent (i.e. continuous)
- A prior clinical Brain MRI with and without contrast done in the past 3 years that does not show signs of clinically significant brain lesions (no evidence of multiple sclerosis, stroke, brain tumor, cortical heterotopia or other cortical developmental abnormalities, arteriovenous malformation, etc…)
Exclusion Criteria:
- Syndrome meeting criteria for Hallucinogen-persisting perception disorder
- Prior treatment with TMS for any disorder
- Epilepsy, family history of epilepsy, or personal history of seizure
- Any medical condition or medication that increases the risk of seizure
- Pacemaker or other implantable medical device
- Metal in the skull, not including the mouth
- Unstable cardiac, pulmonary, or other systemic illness
- Pregnancy
- Bipolar disorder
- History of suicidality
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: One group
All participants will undergo 2 weeks (5 times each week) of repetitive TMS
|
Five days a week for 2 consecutive weeks, participants will have repetitive TMS at specific paramaters
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
TMS Side Effect Questionnaire
Time Frame: Week 1
|
The TMS Side Effect Questionnaire queries participants for specific and potential side effects related to TMS.
It also allows for open ended answers regarding potential side effects from TMS.
The percent of participants experiencing adverse events directly related to treatment will be reported.
|
Week 1
|
TMS Side Effect Questionnaire
Time Frame: Week 2
|
The TMS Side Effect Questionnaire queries participants for specific and potential side effects related to TMS.
It also allows for open ended answers regarding potential side effects from TMS.The percent of participants experiencing adverse events directly related to treatment will be reported.
|
Week 2
|
TMS Side Effect Questionnaire
Time Frame: Month 1
|
The TMS Side Effect Questionnaire queries participants for specific and potential side effects related to TMS.
It also allows for open ended answers regarding potential side effects from TMS.The percent of participants experiencing adverse events directly related to treatment will be reported.
|
Month 1
|
TMS Side Effect Questionnaire
Time Frame: Month 3
|
The TMS Side Effect Questionnaire queries participants for specific and potential side effects related to TMS.
It also allows for open ended answers regarding potential side effects from TMS.
The percent of participants experiencing adverse events directly related to treatment will be reported.
|
Month 3
|
Visual Noise Task
Time Frame: Week 1
|
This task will assess physiological properties of the visual system related to visual noise and will measure luminance increment detection threshold in a noise task with scores from 0-7, with higher scores considered poorer performance.
|
Week 1
|
Visual Noise Task
Time Frame: Week 2
|
This task will assess physiological properties of the visual system related to visual noise and will measure luminance increment detection threshold in a noise task with scores from 0-7, with higher scores considered poorer performance.
|
Week 2
|
Visual Noise Task
Time Frame: Month 1
|
This task will assess physiological properties of the visual system related to visual noise and will measure luminance increment detection threshold in a noise task with scores from 0-7, with higher scores considered poorer performance.
|
Month 1
|
Visual Noise Task
Time Frame: Month 3
|
This task will assess physiological properties of the visual system related to visual noise and will measure luminance increment detection threshold in a noise task with scores from 0-7, with higher scores considered poorer performance.
|
Month 3
|
Visual Contrast Task
Time Frame: Week 1
|
This task will assess physiological properties of the visual system related to contrast and will measure the suppression index for a center-surround suppression task with scores from -1.00 to +1.00, with lower scores considered poorer performance
|
Week 1
|
Visual Contrast Task
Time Frame: Week 2
|
This task will assess physiological properties of the visual system related to contrast and will measure the suppression index for a center-surround suppression task with scores from -1.00 to +1.00, with lower scores considered poorer performance
|
Week 2
|
Visual Contrast Task
Time Frame: Month 1
|
This task will assess physiological properties of the visual system related to contrast and will measure the suppression index for a center-surround suppression task with scores from -1.00 to +1.00, with lower scores considered poorer performance
|
Month 1
|
Visual Contrast Task
Time Frame: Month 3
|
This task will assess physiological properties of the visual system related to contrast and will measure the suppression index for a center-surround suppression task with scores from -1.00 to +1.00, with lower scores considered poorer performance
|
Month 3
|
Global Motion Task
Time Frame: Week 1
|
Each test will assess physiological properties of the visual system related to global motion and measure pattern coherence threshold for global motion task with scores from 0.00 to 1.00, with higher thresholds considered poorer performance.
|
Week 1
|
Global Motion Task
Time Frame: Week 2
|
Each test will assess physiological properties of the visual system related to global motion and measure pattern coherence threshold for global motion task with scores from 0.00 to 1.00, with higher thresholds considered poorer performance.
|
Week 2
|
Global Motion Task
Time Frame: Month 1
|
Each test will assess physiological properties of the visual system related to global motion and measure pattern coherence threshold for global motion task with scores from 0.00 to 1.00, with higher thresholds considered poorer performance.
|
Month 1
|
Global Motion Task
Time Frame: Month 3
|
Each test will assess physiological properties of the visual system related to global motion and measure pattern coherence threshold for global motion task with scores from 0.00 to 1.00, with higher thresholds considered poorer performance.
|
Month 3
|
Colorado Visual Snow Symptom Scale
Time Frame: Week 1
|
Colorado Visual Snow Scale is a novel scale created for this study and to investigate its use in measure symptom severity.
There are 11 subscales: Visual Static, Afterimages, Trails, Blue Field Entoptic Phenomenon, Floaters, Night Vision Problems, Tinnitus, Feeling of Detachment, Anxiety, Depression, Sleep Issues.
Each section assess symptom severe, impact on vision, impact on daily activities, and ability to drive with scale of 0-10 wiht 10 being more severe or impairing the symptom.
Total score for each subscale can range from 0-40 and total score overall can range from 0-440 and the higher the score the more severe or impairing the symptoms.
|
Week 1
|
Colorado Visual Snow Symptom Scale
Time Frame: Week 2
|
Colorado Visual Snow Scale is a novel scale created for this study and to investigate its use in measure symptom severity.
There are 11 subscales: Visual Static, Afterimages, Trails, Blue Field Entoptic Phenomenon, Floaters, Night Vision Problems, Tinnitus, Feeling of Detachment, Anxiety, Depression, Sleep Issues.
Each section assess symptom severe, impact on vision, impact on daily activities, and ability to drive with scale of 0-10 wiht 10 being more severe or impairing the symptom.
Total score for each subscale can range from 0-40 and total score overall can range from 0-440 and the higher the score the more severe or impairing the symptoms.
|
Week 2
|
Colorado Visual Snow Symptom Scale
Time Frame: Month 1
|
Colorado Visual Snow Scale is a novel scale created for this study and to investigate its use in measure symptom severity.
There are 11 subscales: Visual Static, Afterimages, Trails, Blue Field Entoptic Phenomenon, Floaters, Night Vision Problems, Tinnitus, Feeling of Detachment, Anxiety, Depression, Sleep Issues.
Each section assess symptom severe, impact on vision, impact on daily activities, and ability to drive with scale of 0-10 wiht 10 being more severe or impairing the symptom.
Total score for each subscale can range from 0-40 and total score overall can range from 0-440 and the higher the score the more severe or impairing the symptoms.
|
Month 1
|
Colorado Visual Snow Symptom Scale
Time Frame: Month 3
|
Colorado Visual Snow Scale is a novel scale created for this study and to investigate its use in measure symptom severity.
There are 11 subscales: Visual Static, Afterimages, Trails, Blue Field Entoptic Phenomenon, Floaters, Night Vision Problems, Tinnitus, Feeling of Detachment, Anxiety, Depression, Sleep Issues.
Each section assess symptom severe, impact on vision, impact on daily activities, and ability to drive with scale of 0-10 wiht 10 being more severe or impairing the symptom.
Total score for each subscale can range from 0-40 and total score overall can range from 0-440 and the higher the score the more severe or impairing the symptoms.
|
Month 3
|
Drop out rate
Time Frame: Month 3
|
The number of participants who drop out will be determined at the end of the study.
|
Month 3
|
Visual Functional Quality Scale (VFQ-25)
Time Frame: Week 1
|
The VFQ-25 is a reliable and valid 25-item version of the 51-item National Eye Institute Visual Function Questionnaire (NEI-VFQ) and it is useful in clinical trials to measure quality of visual functioning.
Scores range from 0-100 with higher scores indicating better quality visual functioning in everyday activities.
|
Week 1
|
Visual Functional Quality Scale (VFQ-25)
Time Frame: Week 2
|
The VFQ-25 is a reliable and valid 25-item version of the 51-item National Eye Institute Visual Function Questionnaire (NEI-VFQ) and it is useful in clinical trials to measure quality of visual functioning.
Scores range from 0-100 with higher scores indicating better quality visual functioning in everyday activities.
|
Week 2
|
Visual Functional Quality Scale (VFQ-25)
Time Frame: Month 1
|
The VFQ-25 is a reliable and valid 25-item version of the 51-item National Eye Institute Visual Function Questionnaire (NEI-VFQ) and it is useful in clinical trials to measure quality of visual functioning.
Scores range from 0-100 with higher scores indicating better quality visual functioning in everyday activities.
|
Month 1
|
Visual Functional Quality Scale (VFQ-25)
Time Frame: Month 3
|
The VFQ-25 is a reliable and valid 25-item version of the 51-item National Eye Institute Visual Function Questionnaire (NEI-VFQ) and it is useful in clinical trials to measure quality of visual functioning.
Scores range from 0-100 with higher scores indicating better quality visual functioning in everyday activities.
|
Month 3
|
General Anxiety Disorder Scale (GAD-7)
Time Frame: Week 1
|
Screening questionnaire that measures the degree of anxiety with scores ranging from 0-21 and higher scores indicate greater anxiety.
Scores of 5, 10, and 15 can be interpreted as representing mild, moderate, and severe levels of anxiety.
|
Week 1
|
General Anxiety Disorder Scale (GAD-7)
Time Frame: Week 2
|
Screening questionnaire that measures the degree of anxiety with scores ranging from 0-21 and higher scores indicate greater anxiety.
Scores of 5, 10, and 15 can be interpreted as representing mild, moderate, and severe levels of anxiety.
|
Week 2
|
General Anxiety Disorder Scale (GAD-7)
Time Frame: Month 1
|
Screening questionnaire that measures the degree of anxiety with scores ranging from 0-21 and higher scores indicate greater anxiety.
Scores of 5, 10, and 15 can be interpreted as representing mild, moderate, and severe levels of anxiety.
|
Month 1
|
General Anxiety Disorder Scale (GAD-7)
Time Frame: Month 3
|
Screening questionnaire that measures the degree of anxiety with scores ranging from 0-21 and higher scores indicate greater anxiety.
Scores of 5, 10, and 15 can be interpreted as representing mild, moderate, and severe levels of anxiety.
|
Month 3
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Principal Investigator, CU School of Medicine
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 20-0424
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Visual Snow Syndrome
-
University of ZurichUSZ FoundationActive, not recruiting
-
Guy's and St Thomas' NHS Foundation TrustNot yet recruitingVisual Snow Syndrome
-
Universitaire Ziekenhuizen KU LeuvenCompleted
-
Fondation Ophtalmologique Adolphe de RothschildWithdrawnVisual Snow SyndromeFrance
-
Guy's and St Thomas' NHS Foundation TrustCompletedVisual Snow Syndrome | Photophobia | Trailing Phenomenon | Visual AuraUnited Kingdom
-
University of UlsterEnrolling by invitationVisual Stress | Meares-Irlen Syndrome | Reading DifficultiesUnited Kingdom
-
Czech Technical University in PragueCharles University, Czech Republic; Ministry of Defence and Armed Forces of...UnknownSnow Properties and Its Modeling for Studying Gas Exchange Under the Simulated Avalanche Snow (SPAM)Accident Caused by Snow AvalancheCzechia
-
Haukeland University HospitalUllevaal University HospitalUnknownAccident Caused by Snow AvalancheNorway
-
Czech Technical University in PragueCharles University, Czech RepublicCompletedAccident Caused by Snow AvalancheCzech Republic
-
Czech Technical University in PragueEnrolling by invitationAccident Caused by Snow AvalancheCzechia
Clinical Trials on Transcranial Magnetic Stimulation device
-
NeuralieveCompletedMigraine With AuraUnited States
-
University of MinnesotaCompletedTreatment Resistant DepressionUnited States
-
Beth Israel Deaconess Medical CenterCompleted
-
Universidad Nacional Autonoma de MexicoUnknownMajor DepressionMexico
-
University of Texas Southwestern Medical CenterNational Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)RecruitingRole of Sex Hormones Along the Neuromechanical AxisUnited States
-
Medical University of South CarolinaCompleted
-
Russian Academy of Medical SciencesCompletedStrokeRussian Federation
-
State University of New York - Upstate Medical...RecruitingHeadache | Brain Concussion | Mild Traumatic Brain Injury | Post-Concussion SymptomsUnited States
-
George Mason UniversityMedStar National Rehabilitation NetworkCompletedStroke | Stroke, Ischemic | Hemiparesis | Cerebral Vascular AccidentUnited States
-
Centre hospitalier de l'Université de Montréal...Canadian Institutes of Health Research (CIHR)RecruitingMajor Depressive DisorderCanada